Primary Liver Lymphoma: A Case Report and Literature Review

Bourhafour Mouna, Allam Wafae, M’rabti Hind, Errihani Hassan

.

DOI: 10.4236/jct.2011.25098                

Abstract

Primary non-Hodgkin lymphoma of liver is a very rare malignancy. The disease is poorly understood and few clinical studies have been conducted to help elucidate the natural course of disease, pathogenesis, optimal therapy, response to therapy, and survival. Here, we present an interesting case of primary non-Hodgkin lymphoma (NHL) originating in liver. A literature review of clinical features, diagnosis, and management is also provided.

Keywords

Non-Hodgkin Lymphoma, Liver, Hepatic Tumor, Primary Liver Lymphoma, Chemotherapy, Rituximab

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	V. Noronha, N. Q. Shafi, J. A. Obando and S. Kummar, “Primary Non-Hodgkin’s Lymphoma of the Liver,” Critical Reviews in Oncology/Hematology, Vol. 53, 2005, pp. 199-207. doi:10.1016/j.critrevonc.2004.10.010
[2]	A. Masood, S. Kairouz, K. H. Hudhud, A. Z. Hegazi and A. Banu, “Primary Non-Hodgkin Lymphoma of Liver,” Current Oncology, Vol. 16, No. 4, 2009, pp. 74-79. doi:10.3747/co.v16i4.443
[3]	F. S. Haider, R. Smith and S. Khan, “Primary Hepatic Lymphoma Presenting as Fulminant Hepatic Failure with Hyperferritinemia: A Case Report,” Journal of Medical Case Reports, Vol. 2, 2008, p. 279. doi:10.1186/1752-1947-2-279
[4]	J. S. Salmon, M. A. Thompson, R. C. Arildsen and J. P. Greer, “Non-Hodgkin’s Lymphoma Involving the Liver: Clinical and Therapeutic Considerations,” Clinical Lymphoma, Myeloma & Leukemia, Vol. 6, No. 4, 2006, pp. 273-280. doi:10.3816/CLM.2006.n.001
[5]	R. D. Page, J. E. Romaguera, B. Osborne, et al., “Primary Hepatic Lymphoma: Favorable Outcome after Combination Chemotherapy,” Cancer, Vol. 92, No. 8, 2001, pp. 2023-2029. doi:10.1002/1097-0142(20011015)92:8<2023::AID-CNCR1540>3.0.CO;2-B
[6]	K. Coenegrachts, D. Vanbeckevoort, K. Deraedt and W. Van Steenbergen, “Mri Findings in Primary Non-Hodgkin’s Lymphoma of the Liver,” JBR-BTR, Vol. 88, No. 1, 2005, pp. 17-19.
[7]	V. Noronha, N. Q. Shafi, J. A. Obando and S. Kummar, “Primary Non-Hodgkin’s Lymphoma of the Liver,” Critical Reviews in Oncology/Hematology, Vol. 53, No. 3, 2005, pp. 199-207. doi:10.1016/j.critrevonc.2004.10.010
[8]	M. C. Winter and B. W. Hancock, “Ten Years of Rituximab in NHL,” Expert Opinion on Drug Safety, Vol. 8, No. 2, 2009, pp. 223-235. doi:10.1517/14740330902750114
[9]	R. Marcus and A. Hagenbeek, “The Therapeutic Use of Rituximab in Non-Hodgkin’s Lymphoma,” European Journal of Haematology, Vol. 77, No. 6, 2007, pp. 5-14. doi:10.1111/j.1600-0609.2006.00789.x